In conclusion, this study revealed a novel circRNA‐SORE/UBQLN1/GPX4 regulatory axis that mediated sorafenib resistance in HCC and also offered a promising therapeutic strategy to overcome drug resistance and improve clinical outcomes for patients with HCC. Here, UBQLN1 is linked to hepatocellular carcinoma.